<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24178405</article-id><article-id pub-id-type="pmc">4064213</article-id><article-id pub-id-type="publisher-id">IJO-62-407</article-id><article-id pub-id-type="doi">10.4103/0301-4738.120220</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ozsutcu</surname><given-names>Mustafa</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Ayintap</surname><given-names>Emre</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Akkan</surname><given-names>Julide C U</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Koytak</surname><given-names>Arif</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Aras</surname><given-names>Cengiz</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">Department of Ophthalmology, Bezmialem Vakif University, Istanbul, Turkey</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. Mustafa Ozsutcu, Department of Ophthalmology, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey. E-mail: <email xlink:href="opdrmustafa@hotmail.com">opdrmustafa@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2014</year></pub-date><volume>62</volume><issue>4</issue><fpage>407</fpage><lpage>411</lpage><history><date date-type="received"><day>15</day><month>5</month><year>2012</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2013</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Aims:</title><p>To evaluate the efficacy of repeated bevacizumab injection in rotational conjunctival flap surgery versus rotational conjunctival flap with adjunctive mitomycin C (MMC) or rotational conjunctival flap alone.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>Ninety eyes of 90 patients who underwent primary pterygium surgery with rotational flap were evaluated. Patients were randomly assigned to undergo conjunctival rotational flap alone (Group A) or conjunctival rotational flap with either 0.02% MMC application (Group B) or adjunctive subconjunctival 2.5 mg/0.1 ml bevacizumab injection (Group C). Each group consisted of 30 eyes. Recurrence rates at 9 months were evaluated.</p></sec><sec id="st3"><title>Results:</title><p>There were no statistically significant differences in mean size of the pterygium across the limbus in terms of length (<italic>P</italic> &#x0003e; 0.5). The recurrence rates at 9 months were 26.6% (<italic>n</italic> = 8) in Group A, 13.3% (<italic>n</italic> = 4) in Group B, and 10% (<italic>n</italic> = 3) in Group C. The recurrence rates in Group B and C were significantly lower than in Group A (<italic>P</italic> =0.1806). The recurrence rates were similar in Group B and C (<italic>P</italic> &#x0003e; 0.05).</p></sec><sec id="st4"><title>Conclusions:</title><p>Subconjunctival bevacizumab injection may decrease the recurrence rate of primary pterygium surgery with rotational conjunctival flap. Further studies with a larger population and longer follow-up period are needed to supplement this study.</p></sec></abstract><kwd-group><kwd>Mitomycin C</kwd><kwd>pterygium recurrence</kwd><kwd>pterygium surgery</kwd><kwd>subconjunctival bevacizumab injection</kwd></kwd-group></article-meta></front><body><p>A pterygium is a wing-shaped growth of fibrovascular conjunctival tissue onto the cornea. Several hypotheses have been ascribed to its etiology. Prevalence rates range from 0.7-31% in various populations around the world and the condition is more common in warm, dry climates.[<xref rid="ref1" ref-type="bibr">1</xref>] Ultraviolet radiation exposure is a major risk factor for its development.[<xref rid="ref2" ref-type="bibr">2</xref>]</p><p>Treatment of pterygium is surgical and includes simple excision (the bare sclera technique) and excision with grafting (conjunctival or amniotic membrane grafts).[<xref rid="ref3" ref-type="bibr">3</xref>] Simple excision carries a high recurrence rate, ranging from 24-89%.[<xref rid="ref4" ref-type="bibr">4</xref>] Adjunctive treatments; including radiation, antimetabolites, conjunctival grafts, and limbal grafts; are used to reduce the rate of recurrence after surgical excision.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>]</p><p>Some findings suggest that an immunologic dysfunction plays a role in the pathogenesis of pterygium, and recent studies have shown that pterygia have increased levels of proangiogenic growth factors such as basic fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF).[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>] However, the most prominent of these factors is VEGF, which is the main target of many current antiangiogenic therapies, including treatment with bevacizumab, a full-length humanized monoclonal antibody that binds VEGF and antagonizes its effects.[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref>] Topical or subconjunctival bevacizumab has been shown to be effective in treating corneal neovascularization in an <italic>in vivo</italic> animal study and in a recent case report.[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref>]</p><p>Another alternative adjunct is mitomycin C (MMC). Addition of MMC at various concentrations has been reported to be effective in preventing recurrence.[<xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] The mechanism of action seems to be inhibition of fibroblast proliferation at the level of the episclera. However, MMC may cause devastating complications such as scleral necrosis and microbial infections.[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>]</p><p>In the present study, we compared the efficacy of rotational conjunctival flap alone versus rotational conjunctival flap combined with either MMC application on bare sclera or twice-repeated subconjunctival bevacizumab injections.</p><sec sec-type="materials|methods" id="sec1-1"><title>Materials and Methods</title><p>A prospective, comparative, blind, interventional clinical study was carried out from December 2009 until December 2011 Ninety eyes of 90 subjects with primary pterygia were included in the study. Informed consent was obtained from all patients before enrolment. The study was approved by the Bezmi Alem Vakif University Ethics Committee. All patients underwent full ophthalmologic examination before and after surgery, including visual acuity, slit-lamp examination, fundoscopy, and applanation tonometry. Exclusion criteria were collagen vascular disease or other autoimmune disease, pregnancy, ocular surface pathology or infection, and previous limbal surgery.</p><p>All 90 patients underwent rotational flap surgery performed by a single surgeon. The surgical technique was as follows: (i) subconjunctival anesthetic injection in the area to be excised; (ii) excision of the pterygium [<xref ref-type="fig" rid="F1">Fig. 1</xref>]; (iii) light cautery for hemostasis; (iv) a U-shaped incision and preparation of the flap [<xref ref-type="fig" rid="F2">Fig. 2</xref>]; and (v) suturation of the flap with 8-0 vicryl suture [<xref ref-type="fig" rid="F3">Fig. 3</xref>]. Patients were randomized into three groups according to the last numerical digit of their medical records. Group A: Pterygium excision and rotational conjunctival flap on 30 eyes. Subconjunctival balanced salt solution was injected as a placebo. Group B: Pterygium excision and rotational conjunctival flap with adjunctive topical mitomycin C (0.02%) administered to the bare sclera on 30 eyes of 30 patients for 3 min. Group C: Pterygium excision and rotational conjunctival flap with adjunctive subconjunctival bevacizumab (2.5 mg/0.1 ml) injection performed on 30 eyes of 30 patients. Injections were given to the inferior fornix in order to prevent flap contraction. As per our protocol, all eyes received two subconjunctival bevacizumab injections, the first intraoperatively and the second at 1 week after the surgery. All patients were followed for 9 months by two independent examiners and recurrence rates were assessed at 3, 6, and 9 months. Recurrence was defined as any fibrovascular growth of conjunctival tissue extending more than 1.5 mm across the limbus.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Excision of the pterygium tissue</p></caption><graphic xlink:href="IJO-62-407-g001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Preparation and testing the flap size</p></caption><graphic xlink:href="IJO-62-407-g002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Appearance of the flap after suturation with 8-0 vicryl suture</p></caption><graphic xlink:href="IJO-62-407-g003"/></fig><p>Postoperatively, patients were treated with topical Tobradex (tobramycin and dexamethasone, Alcon Laboratories Ltd, Fort Worth, Texas, USA) eye drops four times daily for 1 week. Follow-up visits were at day 1; week 1; and months 1, 3, 6, and 9. Data were analyzed using SPSS version 10.0 software.</p></sec><sec sec-type="results" id="sec1-2"><title>Results</title><p>This study was conducted on 90 patients. There were no statistically significant differences between the groups regarding sex (<italic>P</italic> =0.67) or age (<italic>P</italic> =0.68) [<xref ref-type="table" rid="T1">Table 1</xref>]. All patients had a pterygium on the medial side of the cornea and there were no statistically significant differences in mean size of the pterygium across the limbus (in length) (<italic>P</italic> =0.71). All patients completed the study. Patients were followed postoperatively for 9 months. The main outcome measure was postoperative recurrence. At 9 months postoperatively, the recurrence rate was 26.6% (<italic>n</italic> = 8) in Group A, 13.3% (<italic>n</italic> = 4) in Group B, and 10% (<italic>n</italic> = 3) in Group C [<xref ref-type="table" rid="T2">Table 2</xref>]. The recurrence rates in Group B and C were significantly lower than in Group A (<italic>P</italic> =0.1806). The recurrence rates were found to be similar in Group A and B (<italic>P</italic> &#x0003e; 0.05). No complications related to MMC application or bevacizumab injection were seen during the follow-up period.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline demographics of patients</p></caption><graphic xlink:href="IJO-62-407-g004"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Number of recurrences</p></caption><graphic xlink:href="IJO-62-407-g005"/></table-wrap></sec><sec sec-type="discussion" id="sec1-3"><title>Discuss&#x00131;on</title><p>A pterygium is characterized by excessive fibrovascular proliferation on the exposed ocular surface. It is thought to be caused by increased ultraviolet light exposure due to climatic factors and aggravated by microtrauma and chronic inflammation from environmental factors.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref>] Despite the multifactorial pathogenesis, surgery is the mainstay of treatment. The primary concern in pterygium surgery is recurrence, defined by regrowth of the fibrovascular tissue across the limbus and onto the cornea. In order to reduce the rate of recurrence, various modalities have been proposed. The majority of medical modalities involve measures to counter the fibrovascular activities that play key roles in pterygium recurrence.[<xref rid="ref20" ref-type="bibr">20</xref>]</p><p>Generally, pterygium recurrences happen during the first 6 months after surgery. A number of factors such as the type of pterygium, age of the patient, environmental agents, and surgical technique may be responsible.[<xref rid="ref14" ref-type="bibr">14</xref>]</p><p>Rotational conjunctival flaps to cover the pterygium excisional site have been employed since the 1940s.[<xref rid="ref21" ref-type="bibr">21</xref>] Of the surgical interventions, these are associated with a recurrence rate of 2&#x02013;39%. In our study, we followed 30 pterygium patients treated with the flap technique alone; the recurrence rate in this group was 26.6%. There were no serious complications in these cases. The most frequent symptom after this procedure was the formation of folds over the conjunctiva as a result of rotated tissues in the flap area. Although these folds can result in unsatisfactory cosmesis, including hyperemia at the beginning, after a time the conjunctiva improves and reaches an acceptable level cosmetically. Conjunctival flap tissue that is placed over bare sclera is adjacent to the excised pterygium tissue, and altered limbal cells that might be localized on the flap could contribute to the development of recurrence. We prefer this classical technique because it is easy to apply, but it also demonstrates that surgery alone cannot prevent recurrence.</p><p>The mechanism of action of MMC in the prevention of pterygium recurrence has been attributed to the inhibition of fibroblast proliferation of the episclera.[<xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr">23</xref>] MMC has a prolonged, if not permanent, effect on suppressing human fibroblasts. This prevents the development of fibrosis and aggressive wound healing that is responsible for pterygium recurrence. Adjunctive MMC for pterygium surgery was first described by Kunitomo and Mori in Japan in 1963. In an attempt to decrease ocular morbidity, the intraoperative use of MMC applied directly to the scleral bed has gained increasing acceptance. In this technique, after bare sclera excision, 0.2-0.4 mg/ml MMC is applied directly to the scleral bed for 2-5 min.[<xref rid="ref24" ref-type="bibr">24</xref>] The advantages of this technique include a lower MMC dosage, the use of MMC only in the operating room, and application of MMC directly to the area of pathology rather than to the entire ocular surface.</p><p>In Group B, where MMC was used intraoperatively at a concentration of 0.2 mg/ml over bare sclera for 3 min, the rate of recurrence was 20% in comparison with 38% reported by Chen <italic>et al</italic>.,[<xref rid="ref25" ref-type="bibr">25</xref>] and 10.5% by Manning <italic>et al</italic>.,[<xref rid="ref26" ref-type="bibr">26</xref>] with the application of 0.4 mg/ml for 3 min. This concurs with previous studies on intraoperative application of MMC with a rate of recurrence of 25%.[<xref rid="ref27" ref-type="bibr">27</xref>] Various concentrations of MMC with different durations of application have been used, but the minimal safe and effective dosage and application time are still not certain.[<xref rid="ref13" ref-type="bibr">13</xref>] Rubinfeld and colleagues[<xref rid="ref15" ref-type="bibr">15</xref>] described scleral ulceration, necrotizing scleritis, perforation, iridocyclitis, cataract, infection, glaucoma, scleral calcification, and loss of an eye after pterygium excision with adjunctive MMC therapy. While the exact incidence of these complications is unknown, the safety of MMC therapy remains to be determined with future long-term trials.</p><p>The most common cause of recurrent pterygium is surgical trauma and the histopathological components include neovascularization and fibroblast proliferation. VEGF transcription and secretion are elevated in acute wounds, which mainly promotes the early events in angiogenesis, particularly endothelial cell migration and proliferation.[<xref rid="ref28" ref-type="bibr">28</xref>] Because of this, many studies have focused on the efficacy and safety of avastin in ocular surface disorders. Kheirkhah <italic>et al</italic>.,[<xref rid="ref29" ref-type="bibr">29</xref>] reported a significant role for inflammation in the induction of recurrence after pterygium surgery. They suggested that decreased angiogenic inhibitors together with increased stimulators might play a role in the formation and progression of pterygia. Thus, blocking VEGF, a crucial factor in wound healing, may result in a reduction in both fibrovascular tissue formation and the overall recurrence rate.</p><p>A case report demonstrated the efficacy of 2.5% topical bevacizumab administered four times daily for 3 weeks in inhibiting the recurrence in a patient with impending recurrent pterygium.[<xref rid="ref30" ref-type="bibr">30</xref>] Bahar <italic>et al</italic>.,[<xref rid="ref31" ref-type="bibr">31</xref>] reported on five patients with recurrent pterygium who received subconjunctival bevacizumab twice (2.5 mg/0.1 ml); at a 3-month follow-up no regression of corneal vessels in the recurrent pterygium was observed. Teng <italic>et al</italic>.,[<xref rid="ref32" ref-type="bibr">32</xref>] reported that treatment of primary pterygium with subconjunctival bevacizumab (1.25 mg/0.05 ml) resulted in a short-term decrease in vascularization and irritation in one patient at 7 weeks of follow-up.[<xref rid="ref32" ref-type="bibr">32</xref>] Fallah <italic>et al</italic>.,[<xref rid="ref33" ref-type="bibr">33</xref>] evaluated the efficacy of intralesional bevacizumab injection (2.5 mg/0.1 ml), without rotational conjunctival flap, in reducing the size of pterygia and found it to be fairly effective and well tolerated. The mean percentage decrease of lesion size was 3.97 &#x000b1; 3.84%. Razeghinejad <italic>et al</italic>.,[<xref rid="ref34" ref-type="bibr">34</xref>] reported that a single intraoperative subconjunctival bevacizumab injection (1.25 mg/0.1 ml) had no effect on recurrence rate or early postoperative conjunctival erythema, lacrimation, photophobia, or healing of corneal epithelial defects following pterygium excision in 15 patients. In contrast to the finding of Razeghinejad <italic>et al</italic>.,[<xref rid="ref34" ref-type="bibr">34</xref>] with respect to recurrence, we detected a decrease in recurrence rate after two subconjunctival bevacizumab injections (the first intraoperatively and the second at 1 week post-surgery, each 2.5 mg/0.1 ml). Because of this difference, it may be suggested to repeat the injection after the operation and apply a higher dose of bevacizumab.</p><p>In summary, in the present study we performed pterygium excision with a rotational flap technique in 90 eyes of 90 patients. Patients were divided into three groups, receiving rotational flap alone or with adjunctive 0.2 mg/ml MMC application or 2.5 mg/0.1 ml subconjunctival bevacizumab injection. The first bevacizumab injection was performed at the end of the surgery and the second 1 week after surgery to inhibit the acute phase of fibrovascular activity. Injections were performed in the inferior fornix in order to prevent conjuctival contraction around the wound site. When recurrence rates were compared at 9 months, both MMC application and subconjunctival bevacizumab injection had significantly less recurrence than rotational flap alone. No side effects related to bevacizumab injection were observed during the follow-up.</p><p>The limitations of the study were the short follow-up period and the moderate size of the study groups. With a longer follow-up period, recurrence rates and side effects related to the adjunctive drugs could be analyzed more accurately. Larger sample sizes could make the statistical analyses stronger. Nevertheless, this study showed that subconjunctival bevacizumab injection after primary pterygium surgery with the rotational flap technique had similar recurrence rates to MMC application but without the possible serious complications of MMC.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tasman</surname><given-names>W</given-names></name><name><surname>Jaeger</surname><given-names>EA</given-names></name></person-group><article-title>Duane's Clinical Ophthalmology</article-title><year>2002</year><volume>6</volume><publisher-loc>Philadelphia</publisher-loc><publisher-name>Lippincott Williams and Wilkins</publisher-name><fpage>35</fpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>DJ</given-names></name><name><surname>Hollows</surname><given-names>FC</given-names></name></person-group><article-title>Pterygium and ultraviolet radiation: A positive correlation</article-title><source>Br J Ophthalmol</source><year>1984</year><volume>68</volume><fpage>343</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">6712914</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabhasawat</surname><given-names>P</given-names></name><name><surname>Tesavibul</surname><given-names>N</given-names></name><name><surname>Leelapatranura</surname><given-names>K</given-names></name><name><surname>Phonjan</surname><given-names>T</given-names></name></person-group><article-title>Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><fpage>1102</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16730066</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaros</surname><given-names>PA</given-names></name><name><surname>DeLuise</surname><given-names>VP</given-names></name></person-group><article-title>Pingueculae and pterygia</article-title><source>Surv Ophthalmol</source><year>1988</year><volume>33</volume><fpage>41</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">3051468</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frucht-Pery</surname><given-names>J</given-names></name><name><surname>Siganos</surname><given-names>CS</given-names></name><name><surname>Ilsar</surname><given-names>M</given-names></name></person-group><article-title>Intraoperative application of topical mitomycin C for pterygium surgery</article-title><source>Ophthalmology</source><year>1996</year><volume>103</volume><fpage>674</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8618770</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>MJ</given-names></name><name><surname>Cano-Parra</surname><given-names>J</given-names></name><name><surname>Navea-Tejerina</surname><given-names>A</given-names></name><name><surname>Cisneros</surname><given-names>AL</given-names></name><name><surname>Vila</surname><given-names>E</given-names></name><name><surname>Menezo</surname><given-names>JL</given-names></name></person-group><article-title>Inefficacy of low-dose intraoperative fluorouracil in the treatment of primary pterygium</article-title><source>Arch Ophthalmol</source><year>1995</year><volume>113</volume><fpage>1356</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7487587</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kria</surname><given-names>L</given-names></name><name><surname>Ohira</surname><given-names>A</given-names></name><name><surname>Amemiya</surname><given-names>T</given-names></name></person-group><article-title>Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in pterygium</article-title><source>Acta Histochem</source><year>1996</year><volume>98</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">8739304</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aspiotis</surname><given-names>M</given-names></name><name><surname>Tsanou</surname><given-names>E</given-names></name><name><surname>Gorezis</surname><given-names>S</given-names></name><name><surname>Ioachim</surname><given-names>E</given-names></name><name><surname>Skyrlas</surname><given-names>A</given-names></name><name><surname>Stefaniotou</surname><given-names>M</given-names></name><etal/></person-group><article-title>Angiogenesis in pterygium: Study of microvessel density, vascular endothelial growth factor, and thrombospondin-1</article-title><source>Eye (Lond)</source><year>2007</year><volume>21</volume><fpage>1095</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">16823458</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosseini</surname><given-names>H</given-names></name><name><surname>Nejabat</surname><given-names>M</given-names></name><name><surname>Khalili</surname><given-names>MR</given-names></name></person-group><article-title>Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia</article-title><source>Med Hypotheses</source><year>2007</year><volume>69</volume><fpage>925</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17367957</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Hillan</surname><given-names>KJ</given-names></name><name><surname>Novotny</surname><given-names>W</given-names></name></person-group><article-title>Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy</article-title><source>Biochem Biophys Res Commun</source><year>2005</year><volume>333</volume><fpage>328</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">15961063</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barros</surname><given-names>LF</given-names></name><name><surname>Belfort</surname><given-names>R</given-names><suffix>Jr</suffix></name></person-group><article-title>The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea</article-title><source>An Acad Bras Cienc</source><year>2007</year><volume>79</volume><fpage>389</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">17768531</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manzano</surname><given-names>RP</given-names></name><name><surname>Peyman</surname><given-names>GA</given-names></name><name><surname>Khan</surname><given-names>P</given-names></name><name><surname>Carvounis</surname><given-names>PE</given-names></name><name><surname>Kivilcim</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)</article-title><source>Br J Ophthalmol</source><year>2007</year><volume>91</volume><fpage>804</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17179168</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Wong</surname><given-names>AK</given-names></name><name><surname>Fan</surname><given-names>DS</given-names></name><name><surname>Chew</surname><given-names>S</given-names></name><name><surname>Kwok</surname><given-names>PS</given-names></name><name><surname>Tso</surname><given-names>MO</given-names></name></person-group><article-title>Intraoperative mitomycin C to prevent recurrence of pterygium after excision: A 30-month follow-up study</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>901</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9593395</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutlu</surname><given-names>FM</given-names></name><name><surname>Sobaci</surname><given-names>G</given-names></name><name><surname>Tatar</surname><given-names>T</given-names></name><name><surname>Yildirim</surname><given-names>E</given-names></name></person-group><article-title>A comparative study of recurrent pterygium surgery: Limbal conjunctival autograft transplantation versus mitomycin C with conjunctival flap</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><fpage>817</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">10201608</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinfeld</surname><given-names>RS</given-names></name><name><surname>Pfister</surname><given-names>RR</given-names></name><name><surname>Stein</surname><given-names>RM</given-names></name><name><surname>Foster</surname><given-names>CS</given-names></name><name><surname>Martin</surname><given-names>NF</given-names></name><name><surname>Stoleru</surname><given-names>S</given-names></name><etal/></person-group><article-title>Serious complications of topical mitomycin-C after pterygium surgery</article-title><source>Ophthalmology</source><year>1992</year><volume>99</volume><fpage>1647</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">1454338</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>Seamone</surname><given-names>CD</given-names></name><name><surname>Ostler</surname><given-names>HB</given-names></name><name><surname>Nickel</surname><given-names>BL</given-names></name><name><surname>Beallo</surname><given-names>A</given-names></name></person-group><article-title>Development of scleral ulceration and calcification after pterygium excision and mitomycin therapy</article-title><source>Am J Ophthalmol</source><year>1991</year><volume>112</volume><fpage>343</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">1882947</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Starck</surname><given-names>T</given-names></name><name><surname>Kenyon</surname><given-names>KR</given-names></name></person-group><article-title>The management of pterygium</article-title><source>Ophthalmol Clin North Am</source><year>1990</year><fpage>3611</fpage><lpage>23</lpage></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilgers</surname><given-names>JH</given-names></name></person-group><article-title>Pterygium: Its incidence, heredity and etiology</article-title><source>Am J Ophthalmol</source><year>1960</year><volume>50</volume><fpage>635</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">13714249</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>FD</given-names></name><name><surname>Hirst</surname><given-names>LW</given-names></name><name><surname>Battistutta</surname><given-names>D</given-names></name><name><surname>Green</surname><given-names>A</given-names></name></person-group><article-title>Risk analysis in the development of pterygia</article-title><source>Ophthalmology</source><year>1992</year><volume>99</volume><fpage>1056</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">1495784</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>LP</given-names></name><name><surname>Chua</surname><given-names>JL</given-names></name><name><surname>Tan</surname><given-names>DT</given-names></name></person-group><article-title>Current concepts and techniques in pterygium treatment</article-title><source>Curr Opin Ophthalmol</source><year>2007</year><volume>18</volume><fpage>308</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">17568207</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Krachmer</surname><given-names>JH</given-names></name><name><surname>Mannis</surname><given-names>MJ</given-names></name><name><surname>Holland</surname><given-names>EJ</given-names></name></person-group><article-title>Cornea</article-title><year>1998</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Mosby</publisher-name><fpage>1</fpage></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakaki</surname><given-names>S</given-names></name><name><surname>Marumo</surname><given-names>H</given-names></name><name><surname>Tomioka</surname><given-names>K</given-names></name></person-group><article-title>Isolation of new fractions of antitumor mitomycins</article-title><source>Antibiot Chemother</source><year>1958</year><volume>8</volume><fpage>228</fpage><lpage>40</lpage></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CW</given-names></name><name><surname>Huang</surname><given-names>HT</given-names></name><name><surname>Bair</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name></person-group><article-title>Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma</article-title><source>J Ocul Pharmacol</source><year>1990</year><volume>6</volume><fpage>175</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">2127056</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frucht-Pery</surname><given-names>J</given-names></name><name><surname>Ilsar</surname><given-names>M</given-names></name></person-group><article-title>The use of low-dose mitomycin C for prevention of recurrent pterygium</article-title><source>Ophthalmology</source><year>1994</year><volume>101</volume><fpage>759</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">8152772</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>PP</given-names></name><name><surname>Ariyasu</surname><given-names>RG</given-names></name><name><surname>Kaza</surname><given-names>V</given-names></name><name><surname>LaBree</surname><given-names>LD</given-names></name><name><surname>McDonnell</surname><given-names>PJ</given-names></name></person-group><article-title>A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium</article-title><source>Am J Ophthalmol</source><year>1995</year><volume>120</volume><fpage>151</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">7639298</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>CA</given-names></name><name><surname>Kloess</surname><given-names>PM</given-names></name><name><surname>Diaz</surname><given-names>MD</given-names></name><name><surname>Yee</surname><given-names>RW</given-names></name></person-group><article-title>Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial</article-title><source>Ophthalmology</source><year>1997</year><volume>104</volume><fpage>844</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9160032</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alpay</surname><given-names>A</given-names></name><name><surname>Ugurbas</surname><given-names>SH</given-names></name><name><surname>Erdogan</surname><given-names>B</given-names></name></person-group><article-title>Comparing techniques for pterygium surgery</article-title><source>Clin Ophthalmol</source><year>2009</year><volume>3</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">19668546</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>CR</given-names></name><name><surname>Rojavin</surname><given-names>Y</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Zins</surname><given-names>JE</given-names></name><name><surname>Grana</surname><given-names>G</given-names></name><name><surname>Kann</surname><given-names>B</given-names></name><etal/></person-group><article-title>A review on bevacizumab and surgical wound healing: An important warning to all surgeons</article-title><source>Ann Plast Surg</source><year>2009</year><volume>62</volume><fpage>707</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19461291</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kheirkhah</surname><given-names>A</given-names></name><name><surname>Casas</surname><given-names>V</given-names></name><name><surname>Sheha</surname><given-names>H</given-names></name><name><surname>Raju</surname><given-names>VK</given-names></name><name><surname>Tseng</surname><given-names>SC</given-names></name></person-group><article-title>Role of conjunctival inflammation in surgical outcome after amniotic membrane transplantation with or without fibrin glue for pterygium</article-title><source>Cornea</source><year>2008</year><volume>27</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">18245968</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>PC</given-names></name><name><surname>Kuo</surname><given-names>HK</given-names></name><name><surname>Tai</surname><given-names>MH</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name></person-group><article-title>Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium</article-title><source>Cornea</source><year>2009</year><volume>28</volume><fpage>103</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">19092418</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahar</surname><given-names>I</given-names></name><name><surname>Kaiserman</surname><given-names>I</given-names></name><name><surname>McAllum</surname><given-names>P</given-names></name><name><surname>Rootman</surname><given-names>D</given-names></name><name><surname>Slomovic</surname><given-names>A</given-names></name></person-group><article-title>Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium</article-title><source>Curr Eye Res</source><year>2008</year><volume>33</volume><fpage>23</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18214740</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>CC</given-names></name><name><surname>Patel</surname><given-names>NN</given-names></name><name><surname>Jacobson</surname><given-names>L</given-names></name></person-group><article-title>Effect of subconjunctival bevacizumab on primary pterygium</article-title><source>Cornea</source><year>2009</year><volume>28</volume><fpage>468</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">19411971</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallah</surname><given-names>Tafti MR</given-names></name><name><surname>Khosravifard</surname><given-names>K</given-names></name><name><surname>Mohammadpour</surname><given-names>M</given-names></name><name><surname>Hashemian</surname><given-names>MN</given-names></name><name><surname>Kiarudi</surname><given-names>MY</given-names></name></person-group><article-title>Efficacy of intralesional bevacizumab injection in decreasing pterygium size</article-title><source>Cornea</source><year>2011</year><volume>30</volume><fpage>127</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20885313</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razeghinejad</surname><given-names>MR</given-names></name><name><surname>Hosseini</surname><given-names>H</given-names></name><name><surname>Ahmadi</surname><given-names>F</given-names></name><name><surname>Rahat</surname><given-names>F</given-names></name><name><surname>Eghbal</surname><given-names>H</given-names></name></person-group><article-title>Preliminary results of subconjunctival bevacizumab in primary pterygium excision</article-title><source>Ophthalmic Res</source><year>2010</year><volume>43</volume><fpage>134</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19887878</pub-id></element-citation></ref></ref-list></back></article>